|
November 18, 2005 Running Time: 00:55:30 Intellectual property restrictions rarely impose burdens on genomic and proteomic research, but there are reasons to be apprehensive about their future impact on advances in this field, says a new report from the National Research Council. Policy-makers should take steps to prevent the increasingly complex web of intellectual property protections from getting in the way of potential biomedical breakthroughs. Related Resources:
Speakers: Shirley Tilghman, president, Princeton University, Princeton, N.J. and Roderick McKelvie, partner, Covington & Burling, Washington, D.C.
|
| Subscribe to e-newsletters| Feedback | Back to Top
